AIM ImmunoTech (AIM) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Passage Bio is the larger company by market cap ($11.9 million vs $7.1 million), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | PASG |
|---|---|---|
| Share price | $0.1787 | $3.71 |
| Market cap | $7.13M | $11.94M |
| 1-day change | -0.50% | -0.54% |
| YTD return | — | -67.97% |
| 1-year return | — | -54.35% |
| 5-year return | — | -98.06% |
| EPS (TTM) | $-2.98 | $-11.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $20.00 |
| 52-week low | $0.17 | $3.29 |
| Distance from 52-week high | -93.60% | -81.45% |
| Analyst consensus | none | buy |
| Avg. price target upside | +2278.29% | +317.79% |
| Average volume | 4.70M | 26.11K |
| Shares outstanding | 39.89M | 3.22M |
| Employees | 19 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 24 employees
AIM vs PASG FAQ
Which is bigger, AIM ImmunoTech or Passage Bio?
Passage Bio (PASG) is larger, with a market capitalization of $11.94M compared with $7.13M for AIM ImmunoTech (AIM).
Are AIM ImmunoTech and Passage Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.